ASCO 2017 Bladder Cancer

Viewing 1-20 of 26 articles

ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer

ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin

ASCO 2017: Cabazitaxel in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy: Results of a phase II trial—CAB-B1.

ASCO 2017: Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer

ASCO 2017: Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database

ASCO 2017: Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas

ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

ASCO 2017: Bladder Cancer: 'Novel' Becomes the Norm

ASCO 2017: Intra-patient heterogeneity in urothelial cancer circulating tumor cells and PDL1 expression to identify biomarkers of response and new therapeutic targets

ASCO 2017: Comparison of somatic mutation profiles from cell free DNA versus tissue in metastatic urothelial carcinoma

ASCO 2017: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC)

ASCO 2017: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

ASCO 2017: Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045

ASCO 2017: Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study

ASCO 2017: Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275

ASCO 2017: Phase 3 KEYNOTE-361 trial: Pembrolizumab with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer

ASCO 2017: Predictors of urinary diversion choice in patients with bladder cancer in integrated care settings

ASCO 2017: Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer

ASCO 2017: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC)

ASCO 2017: Management Strategies for Nonurothelial Bladder Cancer

1
2

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.